Molecular Alterations and Biomarkers in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
The promise of precision medicine is now a clinical reality. Advances in our understanding of the molecular genetics of colorectal cancer (CRC) are leading to the development of a variety of biomarkers that are being used as early detection markers, prognostic markers, and markers for predicting treatment responses. This is no more evident than in the recent advances in testing CRCs for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, we update a prior review published in 2010 and describe our current understanding of the molecular pathogenesis of CRC and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers), and the prediction of treatment responses (predictive markers).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 2×
“EGFR-targeted mAbs cetuximab (Erbitux(1)) and the fully humanized mAb panitumumab (Vectibix(1)) have proven to be effective in patients with metastatic CRC both as single agents and in combination with traditional chemotherapy (Ciardiello and Tortora 2008; Cunningham et al. 2004; Saltz et al. 2004).”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 3×
“Results of 4 large phase III randomized have established unequivocally that metastatic CRC patients with KRAS mutations in codon 12 or 13 do not benefit from cetuximab or panitumumab therapy (Amado et al. 2008; Bokemeyer et al. 2009; Karapetis et al. 2008; Van Cutsem et al. 2007).”
BackgroundK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 6×
“2009) and as monotherapy in relapsed/ refractory patients (Amado et al. 2008; Karapetis et al. 2008; Van Cutsem et al. 2007).”
BackgroundInfluentialKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160 · cited 1×
“5-FU-based regimens have been shown to be ineffective or even detrimental to patients with MSI tumors (French et al. 2008; Ribic et al. 2003).”
BackgroundVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 3×
“Results of 4 large phase III randomized have established unequivocally that metastatic CRC patients with KRAS mutations in codon 12 or 13 do not benefit from cetuximab or panitumumab therapy (Amado et al. 2008; Bokemeyer et al. 2009; Karapetis et al. 2008; Van Cutsem et al. 2007).”
BackgroundPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694 · cited 2×
“EGFR-targeted mAbs cetuximab (Erbitux(1)) and the fully humanized mAb panitumumab (Vectibix(1)) have proven to be effective in patients with metastatic CRC both as single agents and in combination with traditional chemotherapy (Ciardiello and Tortora 2008; Cunningham et al. 2004; Saltz et al. 2004).”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“%) of BRAF-WT/KRAS-WT patients (Di Nicolantonio et al. 2008).”
Cited by
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Self-citationColorectal cancer tumour markers and biomarkers: Recent therapeutic advances
Lech, G. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i5.1745 · Cited by 419
Portrait of the PI3K/AKT pathway in colorectal cancer
Danielsen, S. A., Eide, P. W., Nesbakken, A., Guren, T., Leithe, E., & Lothe, R. A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.008 · Cited by 321
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Metadata
- Authors
- Grady, W. M., & Pritchard, C. C.
- Venue
- Toxicologic Pathology
- Publisher
- SAGE Publications
- Published
- 2013-10-31
- Volume
- 42
- Issue
- 1
- Pages
- 124-139
- ISSN
- 0192-6233 (ISSN-L)
- 1533-1601
- OpenAlex
- W2157547728
- Cited by
- 104
- References
- 26
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Alterations and Biomarkers in Colorectal Cancer. https://app.cochat.ai/papers/10.1177/0192623313505155
- The paper
- Grady, W. M., & Pritchard, C. C. (2014). Molecular Alterations and Biomarkers in Colorectal Cancer. Toxicologic Pathology. https://doi.org/10.1177/0192623313505155
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.